RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD

Roche Holding AG

Konzern Hauptsitz
Grenzacherstrasse 124
Basel 4070
Switzerland
41 61 688 11 11
http://www.roche.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees93,734

Key Executives

NameTitlePayExercisedYear Born
Dr. Severin SchwanCEO & Exec. Director8.16MN/A1967
Ms. Cristina A. WilburHead of Group HR2.2MN/A1967
Dr. Alan HippeChief Financial & Information OfficerN/AN/A1967
Dr. Karl MahlerHead of Investor RelationsN/AN/AN/A
Dr. Gottlieb A. KellerGen. Counsel & Corp. Sec.N/AN/A1954
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases. The company provides diagnostic solutions, such as blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring; diabetes therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogeneous immuno assays; immunology; infectious diseases; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control service; real-time PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. Roche Holding AG has a strategic alliance with Wisconsin Diagnostic Laboratories; and collaboration agreements with Five Prime Therapeutics, Inc., Ionis Pharmaceuticals, Inc., SQZ Biotechnologies Company, and Roche. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Corporate Governance

Roche Holding AG’s ISS Governance QualityScore as of December 1, 2018 is 7. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.